Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* Inclusion Criteria:~  * Rectal adenocarcinoma, clinical stage II/III(T3-4 or N+, AJCC 7th), and fulfils the intermediate or locally advanced risk category standard of ESMO recal cancer clinical practice guidelines 2013.~ * KPS status no less than 70; Charlson comorbidity no more than 2; Fit status evaluated by CGA.~ * Life expectancy more than 6 months.~ * Hemoglobin \>= 100g/L, white blood cell \>= 3.5\*10E9/L, neutrophil \>= 1.5\*10E9/L, platelet \>= 100\*10E9/L.~ * Creatin normal, Total bilirubin normal, AST and AST normal, AKP normal.~ * Do not receive surgery ( except palliative colostomy) or chemotherapy or other anti-cancer treatment.~ * No previously pelvic irradiation history.~ * Through MDT discussion, the patient is considered to be candidate for preoperative CRT followed by surgery.~ * Informed consent signed.~* Exclusion Criteria:~  * Other cancer history, except curable non-melanoma skin cancer or cervix in-situ carcinoma.~ * Allergy history to analog of quinazoline folate.~ * Active infection existed.~ * Severe complication, such as acute myocardial infarction in 6 months, uncontrolled diabetes ( Plasma glucose concentrations in any time of a day≥11.1mmol/L）, severe cardiac arrhythmia, etc.~ * Anticipate other clinical trials in four weeks before enrollment.

- Gender: ALL
- Minimum Age: 71 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- preCRT+surgery (Type: EXPERIMENTAL): Treatment including preoperative chemoradiotherapy (preoperative radiation with concurrent chemotherapy) with Raltitrexed followed by surgery. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy or Volumetric-Modulated Arc Therapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on d1 and d22). Pelvic surgery is planned 6 weeks after completion of CRT based on the decision of MDT.

Based on this trial design, predict the completion outcome and termination type (if applicable).